Flow chart of analysis cohort.

<p>Flow chart of analysis cohort.</p

Percentage vaccinated by state.

<p>Alaska and Hawaii not included in this figure for graphical reasons.</p

Person-years by vaccination status and characteristics.

a<p>Individuals could contribute person-time to more than one category.</p>b<p>For determination of numbers, age at vaccination used if vaccinated; otherwise baseline age.</p>c<p>Missing race information for 975 people (0.1%).</p>d<p>At any stage during the study.</p><p>IBD, inflammatory bowel disease; RA, rheumatoid arthritis.</p

Zoster vaccine effectiveness against incident herpes zoster by characteristics and disease definition.

a<p>Definition requiring antiviral administration within 7 d before or after the diagnostic code for herpes zoster.</p>b<p>Adjusted for age, gender, race, low income, COPD, IBD, kidney disease, diabetes mellitus, rheumatoid arthritis, and SLE. Overall estimates were also adjusted for immunosuppression status. Stratified analysis by immune status adjusted for age, gender, race, and low income.</p>c<p>Immunosuppression defined as individuals with leukaemia, lymphoma, and HIV or during and for 6 mo after a prescription for an immunosuppressive drug including oral corticosteroids.</p

Zoster vaccine effectiveness against PHN by characteristics and disease definition.

a<p>Definition requiring antiviral administration within 7 d before or after the diagnostic code for herpes zoster.</p>b<p>Adjusted for age, gender, race, immunosuppression status, low income, COPD, IBD, kidney disease, diabetes mellitus, rheumatoid arthritis, and SLE.</p>c<p>Numbers suppressed to remain compliant with CMS's small-sized cell privacy policy.</p

Incidence rates for herpes zoster by disease definition and patient characteristics.

a<p>Adjusted for age, gender, race, immunosuppression status, low income, COPD, IBD (inflammatory bowel disease), kidney disease, diabetes mellitus, RA (rheumatoid arthritis), and SLE,</p

Association between PDE5 inhibitor use and malignant melanoma, by cumulative number of prescriptions received and time since first prescription (index date).

<p>Cumulative number of prescriptions received (top panel) and time since index date (bottom panel). From a Cox model with age timescale, stratified by matched set and adjusted for number of consultations in year before index date, BMI category, alcohol use, and smoking status.</p

Effect of PDE5 inhibitor use on malignant melanoma risk, stratified by individual-level factors.

<p>From Cox models containing interaction terms between individual-level factors and exposure (interactions fitted one at a time), with age timescale, stratified by matched set and adjusted for number of consultations in year before index date, BMI category, alcohol use, and smoking status.</p

Characteristics of study population.

<p>Characteristics of study population.</p

Characteristics of study population.

<p>Characteristics of study population.</p